Status:
NOT_YET_RECRUITING
Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions:
Esophageal Cancer
Eligibility:
All Genders
18-85 years
Brief Summary
Esophageal cancer is one of the most common malignant tumors worldwide, with high invasiveness and lethality. Currently, the treatment for resectable locally advanced esophageal cancer mainly consists...
Eligibility Criteria
Inclusion
- Patients treated neoadjvant treatment followed by esophagectomy from 2018 to 2023
- Patients with thoracic esophageal squamous cell carcinoma
- The preoperative clnical stage is cT1N+M0/cT2-4aN0-3M0, with potential resectability
- Patients with complete pathological response (ypT0N0M0)
- Without distant metastasis was found in the preoperative examinations, and the tumor did not directly invade the pancreas, spleen, trachea, aorta or other adjacent organs such as the lungs
Exclusion
- Patients with previous history of malignant tumors
- Patients with multiple primary cancers
- Deficient neoadjuvant treatment or salvage surgery
- Incomplete clinical data
Key Trial Info
Start Date :
April 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2025
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06889402
Start Date
April 1 2025
End Date
April 30 2025
Last Update
March 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China, 100021